Fas signaling was reported to participate in cell apoptosis. However, this pathway has also been shown to promote tumor cell motility, leading to the hypothesis that Fas signaling may induce epithelial-mesenchymal transition (EMT) to promote metastasis. The effects of Fas-ligand (FasL) treatment and inhibition of Fas signaling on colorectal and gastric cancer cells were tested using motility assay, immunofluorescence, RT-PCR and immunoblot analyses. Fas signaling downregulated epithelial markers, upregulated mesenchymal markers and promoted motility in gastrointestinal (GI) cancer cells. FasL treatment also increased the expression of EMT transcriptional factors in the nucleus and induced a spindle shape cell morphology in these cells. Knockdown of Snail or Twist expression significantly decreased FasL-induced motility. The ERK1/2 pathway was activated by Fas signaling and is required for FasL-induced EMT and motility. Moreover, oxaliplatin, a chemotherapeutic agent, induced EMT partly through Fas signaling. Evaluation of human GI clinical specimens showed that FasL expression increased whereas E-cadherin expression decreased during GI cancer progression. Both markers were significantly inversely correlated. Tissue samples with a non-EMT phenotype were mainly distributed in patients with early cancer stages, whereas samples with an EMT phenotype were mostly distributed in patients with advanced cancer stages. A non-EMT phenotype significantly correlated with better prognosis. Altogether, these data indicate that Fas signaling may induce EMT to promote tumor motility and metastasis in GI cancer in vivo and in vitro.
INTRODUCTION
Fas (APO-1/CD95), belongs to the TNF and NGF transmembrane receptor superfamily, and activates caspase-dependent apoptosis in susceptible cells when triggered by its cognate ligand, FasL/ CD95L. After Fas-ligand (FasL) binding, the Fas receptor induces recruitment of caspase-8, FADD, and caspase-10 into a complex, which leads to activation of other procaspases, such as caspase-3, and, subsequently cell death. 1 FasL/Fas system can also induce non-apoptotic events in cells, including regulation of cell-cycle progression, 2 cytokine and chemokine expression, 3, 4 tumor growth, 5 motility in apoptosis-resistant cancer cells 6 and liver regeneration. 7 A recent study demonstrated that Fas engagement could induce either a survival or death signal depending on the strength of the stimulus. 8 Low-dose FasL treatment is sufficient to induce non-apoptotic signaling events. Moreover, Fas stimulation in apoptosis-resistant cancer cells can activate various cellular signaling pathways to induce non-apoptotic events, including modulation of NFkB, 6 MAPK 4, 6 and PI3K/AKT. 9 Gastrointestinal (GI) cancer is one of the leading causes of cancer death in the United States. 10 The prognosis for advanced colorectal cancer (CRC) remains dismal, mainly because of the propensity for metastasis and resistance to chemotherapy. 11 Chemotherapeutic drugs can cause upregulation of FasL and Fas, which contributes to the elimination of tumor cells by Fasinduced apoptosis. 12 However, many tumor cells are still resistant to Fas-mediated apoptosis after chemotherapy. 12 Progression or metastasis occurred in 26% of CRC patients after chemotherapy. 13 Therefore, it is possible that chemotherapy-mediated upregulation of FasL and Fas induces tumor proliferation and metastasis in a subset of patients that are resistant to treatment.
Epithelial-mesenchymal transition (EMT)and mesenchymalepithelial transition is a good model to explain how solid tumors metastasize from the site of origin to a new site, although this theory is still under debate.
14 EMT occurs by a series of orchestrated events in which cell-cell and cell-extracellular matrix interactions are altered, and the transition from an epithelial to a mesenchymal phenotype allows for cell movement. 15, 16 During cancer progression, advanced stage cancer cells frequently show downregulation of epithelial markers, which leads to loss of epithelial polarity, intercellular junctions and reduced intercellular adhesion, and these alterations are often accompanied by increased cell motility and expression of mesenchymal markers, 17 indicating EMT process may probably be involved in cancer metastasis. Some cytokines and growth factors can trigger the EMT process. Among them, transforming growth factor-b1 is the most common one that can induce EMT in many epithelial cell types. 17 Recently, it has been reported that in addition to enhancing proliferation, Fas signaling may induce the EMT process allowing for invasion and metastasis in murine apoptosis-resistant colon cancer. 18 Although these data were informative, it still needs to be carefully verified in human cancer in vivo and in vitro.
Fas signaling can promote motility in different apoptosisresistant cancer cells, 6 therefore, in this study we examined whether Fas signaling can promote motility in GI cancer cells and the possible mechanisms required. The novelty of this study is that we use low-dose FasL stimulation and establish the relationship between Fas signaling and the EMT process in vivo and in vitro. We found that Fas signaling could induce EMT to promote motility and metastasis in vivo and in vitro. Furthermore, oxaliplatin, a chemotherapeutic agent, induced EMT, at least in part, by Fas signaling. Hence, any treatment aimed at inducing tumor apoptosis through Fas signaling should be administered cautiously, as this pathway may induce aggressive tumor traits. 18 
RESULTS

Expression of FasL and Fas in GI cancer cell lines
FasL and Fas expression were detected by flow cytometry in all GI cell lines maintained in our lab. We also detected the expression of antiapoptotic proteins, including Bcl-2, Bcl-xl, FLIP and XIAP. There was moderate Fas expression but undetectable FasL expression in DLD1,HT29, HCT116, SW480 and AGS cells (Supplementary Table 1 ). These cell lines were epithelial-like in morphology (data not shown). In contrast, SW620 and LOVO cells had moderate FasL and little Fas expression (Supplementary Table 1) , and were fibroblast-like in morphology (data not shown). SW480, DLD1, AGS and SW620 cells were used for further study. Low-dose FasL (12.5 ng/ml) did not affect the growth of SW480, DLD1 and AGS cells (Supplementary Figure 1) . However, moderate-dose FasL (25 ng/ml) induced apoptosis in DLD1 and AGS cells but not in SW480 cell whereas high-dose FasL (50 ng/ml) induced apoptosis in three cells (Supplementary Figure 1) . Meanwhile, FasL inhibitor, NOK-1, didnot affect the growth of SW620 cells (Supplementary Figure 1) .
Fas signaling promotes migration and invasion in GI cancer cell lines As Fas signaling promotes motility in apoptosis-resistant cell lines, 6 we determined whether low-dose FasL (12.5 ng/ml) Figure 3) . Moreover, cell growth curves were performed under the same experimental conditions and no differences in cell proliferation rates were found (data not shown), excluding any differences in proliferation rates contributing to the above results. Tumor cells most likely encounter FasL in two different forms in vivo: soluble FasL (sFasL) in the serum and membrane-bound FasL (mFasL). mFasL can be found in vivo on different types of cells, including tumor-infiltrating lymphocytes. To test whether human mFasL can also induce an increase in motility, we incubated DLD1 or AGS cells with fixed SW620 cells, which express human mFasL, and performed invasion chamber assays. Contact with cells expressing mFasL significantly increased the motility of both DLD1 (Figure 1f ) and AGS (Supplementary Figure 2C ) cells, and this activity could be fully inhibited by NOK-1 pretreatment, indicating only Fas signaling functions to promote DLD1 and AGS cells motility, not other cytokines secreted by SW620 or other mechanism caused by SW620.
Fas signaling induces EMT to promote motility in GI cancer cell lines The EMT process can promote motility in tumor cells by downregulating epithelial (CDH1) and upregulating mesenchymal markers (Vimentin). 17 To test whether Fas signaling can induce EMT, we performed RT-PCR (Supplementary Table 2 (Figure 3a ). SW480 and DLD1 cells changed from a cobblestone-like morphology to a spindle shape in a monolayer culture after FasL treatment for 3 days (Figure 3b ). Altogether, these data indicate that Fas signaling can induce EMT in GI cancer cells.
Next, we determined whether the FasL-induced increase in motility requires EMT in GI cancer cells. EMT is primarily mediated by transcriptional factors that inhibit epithelial markers and/or increase mesenchymal markers. Snail or Twist was stably knockeddown using a lentiviral shRNA-expressing construct in SW480, DLD1 and AGS cells. Fas signaling activates ERK1/2 to induce EMT and promote motility in GI cancer cells Fas signaling may trigger various cellular pathways to induce nonapoptotic events. 4, 6, 9 Therefore, we performed immunoblot analysis to determine whether the MAPK, NFkB or PI3K/AKT pathways are activated in GI cancer cells after FasL treatment. We found that ERK1/2 and p38 were activated in SW480 cells after FasL stimulation (Figure 5a ), but only ERK1/2 were activated in AGS cells (Supplementary Figure 7A ). Cells were then pretreated with U0126 (10 mM) before FasL treatment to inhibit ERK1/2 activation. Immunoblot and immunofluorescence results show that ERK1/2 inhibition suppresses Fas-induced EMT (Figure 5b 
Oxaliplatin treatment induces EMT partly through Fas signaling in CRC cells
Chemotherapy is commonly used in CRC patients before and after surgery, which can sensitize cancer cells to apoptosis by upregulating Fas and FasL. 12 However, progression or metastasis may also occur in some CRC patients after chemotherapy. 13 Therefore we examined whether chemotherapeutic drugs reported to enhance expression of FasL and Fas, specifically oxaliplatin, 20 can induce EMT through Fas signaling. We treated SW480 and HT29 cells with oxaliplatin (2 mM, the plasma concentration in patients) for 3 days and found that expression of Table 5 ), suggesting that FasL might induce EMT in vivo. As the expression of E-cadherin, an important EMT marker, decreases during the EMT process, we defined FasL( À/þ )/E-cadherin( þ þ / þþ þ ) as non-EMT phenotype samples and FasL( þþ / þþþ )/E-cadherin( À/þ ) Table 6 ), implying that FasL-induced EMT might promote metastasis in vivo. Moreover, expression of EMT markers in clinical samples from GI cancer patients was also detected by immunoblot. We found that, in general, FasL and Vimentin expression increased whereas E-cadherin expression decreased during cancer progression (Figure 7d , Supplementary  Figure 9 and 10), which was consistent with the IHC results. Finally, we wanted to determine whether EMT marker expression can indicate prognosis. Better prognosis was significantly noted in patients with non-EMT phenotype CRC (Figure 7e ) and GC cancers (Supplementary Figure 11) . (Figure 7f ) or GC patients (data not shown) was observed between these two groups.
DISCUSSION
In addition to its ability to induce apoptosis, Fas signaling can also induce non-apoptotic events in tumor cells, such as regulation of tumor growth 5 and motility. 6 In this study, we aimed to investigate whether Fas signaling could enhance motility in GI cancer cells and the possible mechanism by which Fas signaling promotes motility. In summary, we found that Fas signalinginduced EMT to promote motility in vivo and in vitro.
As reported, high-dose FasL (25-50 ng/ml) can induce apoptosis while low-dose FasL can induce non-apoptotic signal events, such as proliferation in gastric adenocarcinoma cells and rat gastric mucosa cells. 8, 19 However, high-dose FasL was also shown to promote motility in apoptosis-and chemotherapy-resistant cancer cells. 6, 21 In this study, we used low-dose FasL to promote motility in GI cancer cells (SW480, DLD1 and AGS). Altogether, both sFasL and mFasL could promote motility in these cell lines that are not apoptosis or chemotherapy resistant.
Fas signaling can promote motility, which leads to metastasis, in GI cancer cells but the mechanism is still unknown. The EMT and mesenchymal-epithelial transition model is a good way to explain how solid tumors metastasize from the site of origin to a new site, although this theory is controversial. 14 Whether FasL, like transforming growth factor-b1, 17 can induce EMT in human GI cancer cells to promote metastasis needed further investigation. To test this hypothesis, we treated SW480, DLD1 and AGS cells that were cobblestone-like in cell culture with FasL and found that epithelial markers decreased whereas mesenchymal markers increased over time.This change was Fas-dependent. Fas signaling is also required to maintain an EMT phenotype in SW620 to some extent. These data suggest that Fas signaling can induce EMT in GI cancer cells. Transcriptional factors, such as Snail and Twist, have an important role in induction of EMT. 17 Herein, we noticed that Fas-signaling induced EMT and promoted motility through different EMT transcriptional factors. This model is similar to the transforming growth factorb-induced EMT process. 22 Fas stimulation in cancer cells may activate various cellular signaling pathways, such as NFkB, 6 MAPK 4-6 and PI3K/AKT, 9 to induce non-apoptotic events. In this study, FasL treatment activated ERK1/2 and p38 in SW480 cells and ERK1/2 in AGS cells. This result is similar to the finding that Ras-RAF-MAPK pathway has an important role in EMT mediated by receptor tyrosine kinases induced by growth factors, such as HGF, VEGF and EGF. 23, 24 It has been reported that the PI3K/AKT signaling pathway can control hypoxia-induced EMT in hepatocellular cancer 25 and promote Fas-induced invasion in apoptosis-resistant glioblastoma cell, 9 whereas the NFkB pathway was shown to be activated by Fas signaling to promote motility in apoptosis-resistant breast cancer cells. 6 Furthermore, Fas signaling-induced JNK activation contributed to tumor growth in mouse and human samples. 5 It seems that FasL induces different signaling pathways in different tumor cells. In addition, a broad caspase inhibitor did not inhibit ERK1/2 activation and the subsequent EMT process. These results are consistent with reports that activation of ERK1/2 by Fas is independent of its death domain. 8, 26 Most chemotherapeutic drugs can sensitize cancer cells to apoptosis by upregulating Fas and/or FasL expression (mFasL and sFasL), including 5-Fu, oxaliplatin, cisplatin and mitomycin. 12, 27 Furthermore, oxaliplatin treatment was shown to induce EMT in CRC cells. 21, 28 It was reported oxaliplatin-chemoresistant colon cancer cells could increase expression of Fas and FasL and acquire a more aggressive phenotype compared with their parental cells. 21, 28 This aggressive phenotype was dependent on Fas signaling. However, the authors didnot confirm the relationship between Fas signaling and EMT in these cells. Moreover, whether the invasive phenotype mediated by chemotherapeutics was a direct or indirect effect is still unknown; it is probably an integrated effect. To address this issue in our model, we used NOK-1 or Fas shRNA to inhibit Fas signaling in CRC cells before oxaliplatin treatment and found that oxaliplatin-induced EMT was partly dependent on Fas signaling. These data indicate the possible mechanism by which chemotherapies promote tumor progression and metastasis.
To verify our results in vivo, IHC was used to analyze expression of FasL and E-cadherin in GI cancerparaffin-embedded samples. Some reports have shown FasL expression increased 29 and E-cadherin decreased 30 during CRC progression, however, this is the first reported study where the expression of these two markers were examined in the same GI cancer samples. We found that both markers inversely correlated in GI cancer specimens, suggesting FasL might induce EMT in vivo. The Fas receptor is frequently downregulated during cancer progression, but complete loss of Fas is rarely observed in human cancers. 5, 31 In fact, many cancer cells express large quantities of Fas (SW480, DLD1 and AGS) and are highly sensitive to Fas-mediated apoptosis in vitro. 5 In addition, tumors from cancer patients frequently have elevated levels of FasL. 5 All of these data raise the possibility that Fas signaling can serve functions to induce non-apoptotic events in vivo, such as EMT. In summary, we demonstrated that Fas signaling can induce EMT to promote motility in GI cancer. Further investigation should be focused on whether Fas signaling can induce EMT and how Fas signaling regulates EMT in other tumor types.
MATERIALS AND METHODS
Cell culture and reagents
All human GI cancer cell lines (Supplementary Table 1) were obtained from American Type Culture Collection (Manassas, VA) and routinely maintained in our lab. These cell lines were cultured in RPMI 1640 with 100 IU/ml penicillin, 100 mg/ml streptomycin and 10% fetal bovine serum in a humidified 5% CO 2 atmosphere at 37 1C. Serum-free medium was used in most experiments unless otherwise indicated. FasL (Alexis, San Diego, CA, USA) was used at 12.5 ng/ml and the FasL inhibitor, NOK-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used at 10 mg/ml. Inhibitors were added into the culture medium 2 h before treatment. All detailed information for reagents and antibodies is listed in the Supplementary Information.
Cell line transfection
Lentiviral shRNA vectors (Santa Cruz Biotechology) targeting human Snail, Twist, Fas and FasL were utilized for stable knockdown in GI cancer cells (Supplementary Figure 12) . Procedures were conducted according to the manufacturer's protocol. Cells resistant to puromycin (10 mg/ml) were selected and passaged for further study.
GI tissue specimens and follow-up
This study was conducted with a total of 188 CRC and 143 GC paraffinembedded samples collected from Nanfang Hospital (Guangzhou, China). All patients did not receive therapy before the study. All tissues were examined by at least two experienced pathologists and checked for the presence of tumor cells. Pathological diagnosis and classification were performed based on the criterion of the International Union Against Cancer. The research protocol was approved by the Ethics Committee of Nanfang Hospital and consents were acquired from all patients for the study. Follow-up data was available for all patients.
IHC
Paraffin-embedded samples were processed using routine IHC procedures as previously described. 32 Stained tissue sections were reviewed and scored separately by two experienced pathologists blinded to the clinical parameters. The scoring method used to evaluate immunostaining was similar to a relatively simple and reproducible protocol. 33 Anti-FasL (Santa cruz, sc-823, N-20) and E-cadherin (BD Bioscience, San Jose, CA, USA BD610181) were used for IHC assay.
Immunoblot
Total protein was extracted in RIPA lysis buffer with protease and phosphotase inhibitors (Roche, Nutley, NJ, USA) and quantified using the BCA method (Thermo Scientific, Waltham, MA, USA). Total protein (50 mg) was resolved by 4-20% SDS polyacrylamide gel electrophoresis (Bio-Rad, Philadelphia, PA, USA) and transferred to nitrocellulose membrane. Membranes were incubated with various antibodies in specific concentrations according to the manufacturer's instructions. Protein expression was detected by ECL (Thermo Scientific).
RT-PCR
Total RNA was extracted using Trizol (Invitrogen, Carlsbad, CA, USA) and cDNA was synthesized by oligo dT primed reverse transcription (Promega, San Luis Obispo, CA, USA) from 2 mg of total RNA. Primers for EMT markers are shown in Supplementary Table 2 . PCR was performed using an ABI thermocycler (Applied Biosystems Inc., Carlsbad, CA, USA). cDNA (1 ml) and primer mix (1 ml) were added into PCR master mix (Promega) for amplification. PCR conditions were as follows: 95 
Cell invasion and migration assay
Invasion chambers (Corning Inc., Corning, NY, USA) were rehydrated at 37 1C and then 50 000 cells (serum-starved for 24 h before the assay) were added to the top chamber in serum-free medium (100 ml) and the bottom chamber was filled with medium containing 10% fetal bovine serum (chemicals were added to both chambers of each well if necessary). Then cells were cultured for 72 h at 37 1C in a 5% CO 2 humidified incubator. To quantify invasion, cells were removed from the top-side of the membrane using a cotton-tipped swab and invading cells attached to bottom of the membrane were fixed with 4% paraformaldehyde and stained with DAPI solution. Cell number from 10 representative fields was counted for each insert using fluorescent microscopy. The average cell number/field from the control group was set as the baseline (onefold), and was compared with the treatment groups (fold-change ¼ treatment group cells/ fieldÄcontrol group cells/field). For some experiments, cells were cultured with inhibitor 2 h before treatment. To test the effect of mFasL, 6 SW620 (mFasL-expressing cells) were fixed in 4% paraformaldehyde and washed extensively before the assay. Then 50 ml of fixed SW620 (40 000 cells, with or without NOK-1 treatment, in serum-free medium) were mixed with 50 ml of live/unfixed DLD1 cells (20 000 cells in serum-free medium). The cell mixture was added into the top chamber and the bottom chamber was filled with 10% fetal bovine serum medium. SW620 cells were fixed in order to only study the migration of DLD1 cells. It has been previously shown that FasL on fixed cells can still activate the receptor on unfixed cells. 6 As a control, fixed DLD1 cells (do not express mFasL; control for SW620 cells) were mixed with live/unfixed DLD1 cells as described above. For the migration assay, transwell insert chambers (Corning Inc.) were used and all procedures were performed as the invasion assay with the exception of membrane rehydration and the incubation time (18 h, Supplementary Figure 13 ). Cell proliferation assays were conducted as previously described. 6 Immunofluorescence Cells grown in chambered coverglass (Thermo Scientific) were fixed with 4% paraformaldehyde and nonspecific binding was blocked by 5% bovine serum albumin in PBS. The cells were probed with primary antibody, washed and then probed with Texas Red goat anti-mouse IgG or goat antirabbit IgG secondary antibody (Santa Cruz). After mounting, the slips were visualized by fluorescence microscopy (Olympus, Tokyo, Japan).
ELISA assay MMP9 and MMP2 (pro-and active-form) secretion in cell culture supernatant was detected by Human Quantikine ELISA Kit (R&D System, Minneapolis, MN, USA) according to the instruction. The average MMP expression from the control group was set as the baseline (one fold) and was compared with the treatment groups (fold-change ¼ treatment group expressionÄcontrol group expression).
Statistical analysis
Statistical analysis was conducted using SPSS 17.0 (SPSS Inc., Chicago, IL, USA). Difference in IHC scoring was calculated by Kruskal-Wallis test, whereas significance between changes in different groups was evaluated by one-way analysis of variance. Least-significant difference test was used for multiple comparisons. Correlation coefficient was calculated by the Spearman's correlation method. A P-value o0.05 was considered statistically significant. ABBREVIATIONS CRC, colorectal cancer; EMT, epithelial-mesenchymal transition; GC, gastric cancer; GI, gastrointestinal; IHC, immunohistochemistry.
